Top 5 Companies To Invest In 2014

It’s back! Already! Can you believe that another major lottery drawing�is here? The Pennsylvania Lottery system has not yet produced a new winner, and the Mega Millions jackpot is now up to $353 million as an estimated annuity value. And if you just want the cash, that estimated cash value is projected to be $194 million.

As no winner picked the winning numbers on Tuesday, the new Jackpot drawing will come this Friday night — March 14, 2014. The real question that lottery players should be asking themselves, outside of whether they really should be buying lotto tickets, is what they should do if they win?

24/7 Wall St. developed a simple 12-step plan for lottery winners. This would be the same sort of plan for individuals who suddenly come into vast sums of money via inheritance, a judgment or other unexpected windfalls. What makes this 12-step program different from so many other online reports is that it is presented in a “what not to do” manner to prove the point outside of financial industry jargon.

Best Dow Dividend Stocks For 2015: Ambit Biosciences Corp (AMBI)

Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Quizartinib

The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.

AC410

The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.

CSF1R Program

The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.

The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.

Advisors' Opinion:

• [By Wallace Witkowski]

  Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.

Top 5 Companies To Invest In 2014: SBA Communications Corporation(SBAC)

SBA Communications Corporation owns and operates wireless communications towers primarily in the United States, Canada, Costa Rica, El Salvador, Guatemala, Nicaragua, and Panama. The company leases antenna space primarily to wireless service providers on towers and other structures that it owns, manages, or leases from others. As of December 31, 2011, it owned 10,524 tower sites. The company also manages or leases approximately 4,800 actual or potential communications sites. In addition, it provides various site development consulting services comprising network pre-design, site audits, identification of potential locations for towers and antennas, support in buying or leasing of the location, and assistance in obtaining zoning approvals and permits, as well as engages in assisting wireless service providers in developing and maintaining wireless service networks. Further, the company offers various site development construction services, including tower and related site c onstruction; antenna installation; and radio equipment installation, commissioning, and maintenance. SBA Communications Corporation was founded in 1989 and is headquartered in Boca Raton, Florida.

Advisors' Opinion:

• [By Jon C. Ogg]

  We just gave a fresh synopsis of which telecom and wireless players could still be up for M&A in the final round of consolidation. American Tower’s market cap is about $28 billion and shares are up more than 4.5% at $71.75. To show how hard things have been, the 52-week trading range is $67.89 to $85.26. What today’s transaction does is quite simply add value to the rest of the public companies that own and operate cell towers:

  Crown Castle International Corp. (NYSE: CCI) is up almost 2.5% at $70.90, against a 52-week range of $63.16 to $81.16. SBA Communications Corp. (NASDAQ: SBAC) is up about 1.8% at $76.70. against a 52-week range of $59.00 to $82.31.

  American Tower expects that the portfolio addition will generate about $345 million in revenues and approximately $270 million of gross margin in 2014. If you value the deal solely on the 5,400 or so owned U.S. towers, this comes up to about $611,000 per tower before calculating the debt and other rights. Suddenly, SBA Communications Corp. (NASDAQ: SBAC) is vindicated because a deal it made in 2012 was deemed pricey as it paid about $1.45 billion for 3,252 towers from TowerCo, at about $445,000 per tower. Crown Castle also has spent close to $2.4 billion to acquire T-Mobile cell tower rights in late 2012.

Top 5 Companies To Invest In 2014: Home Loan Servicing Solutions Ltd (HLSS)

Home Loan Servicing Solutions, Ltd, incorporated on December 1, 2010, is a development-stage company. The Company is formed to acquire mortgage servicing assets, primarily subprime and Alt-A mortgage servicing rights and associated servicing advances. The Company will engage residential mortgage loan servicers to service the pools of mortgage loans underlying the mortgage servicing rights. The Company acquire and therefore do not intend to develop its own mortgage servicing platform.

The Company is focused to enter into the subservicing agreement to provide for the servicing of the initial mortgage servicing rights for an initial term of seven years. As of December 31, 2010, The Company had neither purchased nor contracted to purchase any mortgage servicing assets, including mortgage servicing rights and related servicing advances.

Advisors' Opinion:

• [By David Sterman]

  Although shares of Boulder Brands (Nasdaq: BDBD) are up more than 60% since then, Home Loan Servicing (Nasdaq: HLSS) has merely treaded water while Swift Energy has continued its downward ascent.

• [By Eric Volkman]

  Home Loan Servicing Solutions (NASDAQ: HLSS  ) is servicing its capital base with a new share offering that should total nearly $300 million. The company is floating 13 million shares of its stock in an underwritten public issue at a price of $23 per share. All told, the gross proceeds of the offering should amount to roughly $299 million.

Top 5 Companies To Invest In 2014: Continental Gold Ltd (CGOOF.PK)

Continental Gold Limited is an exploration-stage company. The Company is engaged in the acquisition, exploration, evaluation and development of principally gold resource properties in Colombia. The Company holds the rights to explore and develop six properties in Colombia totaling approximately 122,317 hectares. The Buritica project encompasses an aggregate area of 57,588 hectares and is located about 75 kilometers northwest of Medellin in the Antioquia Department of north-western Colombia. The Berlin project covers an aggregate area of 25,059 hectares. The project area is located 90 kilometers north of Medellin in the Antioquia Department. The Dominical project encompasses an aggregate area of 24,327 hectares and is located in southern Colombia in the Cauca Department. The project area is consists of four registered concessions totaling 5,590 hectares, five pending registration concessions totaling 3,426 hectares and 10 concession applications covering 15,311 hectares. Advisors' Opinion:

• [By Markus Aarnio]

  Other gold miners that have seen intensive insider buying during the past four months include St. Andrew Goldfields (STADF.PK), Continental Gold (CGOOF.PK), Kinross (KGC) and Agnico-Eagle Mines (AEM).